Literature DB >> 18783211

Synthesis of bivalent beta2-adrenergic and adenosine A1 receptor ligands.

Peter Karellas1, Michael McNaughton, Stephen P Baker, Peter J Scammells.   

Abstract

Research in the area of simutaneously targeting more than one G protein-coupled receptor (GPCR) has increased in recent times. By exploiting the cross talk between the beta2-adrenergic (beta2AR) and adenosine A1 receptors (A1AR) on adenylate cyclase activity, we synthesized a series of bivalent agonists for both GPCRs to generate responses from more than one receptor. We have demonstrated a relationship between the various beta2-adrenergic and A1 adenosine bivalent parameters of linker and bifunctionality by using data that are drawn from in vitro assays. The hexyl-linked 12e (K(i), 311 nM) and butyl-linked 12c ( K(i), 863 nM) bivalent compounds displayed reasonable binding affinities for the beta2AR when compared with the control (-)isoproterenol (K(i), 136 nM), and both compounds also exhibited a persuasive bifunctional trend for both receptors at various drug concentrations. The bivalent compound 12e was also found to have significant EC50 potency (6 nM) at the beta2AR in DDT cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18783211     DOI: 10.1021/jm800613s

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Unexpected enhancement in biological activity of a GPCR ligand induced by an oligoethylene glycol substituent.

Authors:  Chutima Jiarpinitnun; Laura L Kiessling
Journal:  J Am Chem Soc       Date:  2010-07-07       Impact factor: 15.419

Review 2.  Polycyclic compounds: ideal drug scaffolds for the design of multiple mechanism drugs?

Authors:  Cornelis J Van der Schyf; Werner J Geldenhuys
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

3.  (R,R')-4'-methoxy-1-naphthylfenoterol targets GPR55-mediated ligand internalization and impairs cancer cell motility.

Authors:  Rajib K Paul; Artur Wnorowski; Isabel Gonzalez-Mariscal; Surendra K Nayak; Karolina Pajak; Ruin Moaddel; Fred E Indig; Michel Bernier; Irving W Wainer
Journal:  Biochem Pharmacol       Date:  2013-12-16       Impact factor: 5.858

Review 4.  New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism.

Authors:  Elizabeth A Vecchio; Jo-Anne Baltos; Anh T N Nguyen; Arthur Christopoulos; Paul J White; Lauren T May
Journal:  Br J Pharmacol       Date:  2018-06-21       Impact factor: 8.739

5.  A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH2 versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2: A Bivalent Advantage.

Authors:  Cody J Lensing; Danielle N Adank; Stacey L Wilber; Katie T Freeman; Sathya M Schnell; Robert C Speth; Adam T Zarth; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2017-02-16       Impact factor: 4.418

6.  An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.

Authors:  Cody J Lensing; Katie T Freeman; Sathya M Schnell; Danielle N Adank; Robert C Speth; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2016-03-29       Impact factor: 7.446

Review 7.  Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).

Authors:  Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2009-04-30       Impact factor: 4.774

8.  2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.

Authors:  Amy Hauck Newman; Francisco O Battiti; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-09-24       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.